MedTrace Logo

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

NCT02696642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-07-09

No results posted yet for this study

Summary

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Conditions

  • Neoplasms

Interventions

DRUG

Anetumab ravtansine (BAY94-9343)

All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-14
Primary Completion
2018-07-31
Completion
2019-08-19

Countries

  • France
  • Moldova

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02696642 on ClinicalTrials.gov